– Signed IVD partnership for Ares Genetics
– Progressed implementation of the Curetis – OpGen business combination with S4 filing
– More than tripled total contract order volume received year-over-year to EUR 3.4 million in 9M-2019
– Revenue growth of approximately 16%
– Near-term FDA decision on clearance of Unyvero LRT for BAL specimen expected
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today published its third quarter and 9-months business and financial update.